A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-072 After Discontinuation of ABT-072 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-072 Clinical Studies
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2013
At a glance
- Drugs ABT 072 (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned end date changed from 1 Jun 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 24 Jul 2009 Planned number of patients changed from 68 to 5 as reported by ClinicalTrials.gov.